Introduction
Evidence suggests that people diagnosed with HIV in resource-rich countries have a life expectancy that is almost equivalent to that in people without HIV if they receive appropriate treatment with combination antiretroviral treatment (cART). 1 However, despite substantial improvements in clinical prognosis, much less is known about the health-related quality-of-life (HRQoL) of individuals with HIV compared with that in the general population. [2] [3] [4] For example, although evidence from studies from the USA show that people with HIV have higher rates of depression than do people without HIV, the eff ect of HIV status on other domains and overall HRQoL is less clear. 4 HRQoL is a multidimensional concept that incorporates factors such as physical, cognitive, emotional, and social functioning. Insight into HRQoL is essential to understand the eff ects of HIV as a chronic disease. Moreover, when measured with socalled utility-based instruments, the information can be used in economic evaluations to help to generate qualityadjusted life-years (QALYs), in which one QALY is equivalent to a year of perfect health. 5 Recent debate has centred around whether people with HIV age more quickly as a result of their HIV status [6] [7] [8] in other words whether they tend to start having ageingrelated ill-health and disability at a younger age than do people without HIV, and whether this diff erence tends to widen with older age. The aim of this study was therefore two-fold: to assess whether individuals with HIV, particularly those who are virologically stable on suppressive treatment, have similar levels of HRQoL compared with the general population, after adjustment for demographic and socioeconomic variables such as age, sex, and smoking status; and to assess whether the diff erence in HRQoL between those with HIV and the general population increases with older age.
Methods

Study population and procedures
We merged data from two large cross sectional questionnaire studies. The fi rst, ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes study), was mainly designed to investigate present patterns of sexual behaviour in individuals with diagnosed HIV in the UK. Full details regarding the study design are available elsewhere. 9 Briefl y, the study includes an unselected sample of 3258 people with HIV recruited from outpatient clinics at eight urban centres in England, between Feb 1, 2011, and Dec 31, 2012; the response rate was 64%. The ASTRA questionnaire was self-completed and available in English and French; information about viral load and CD4 cell count was extracted from clinical records by study personnel. ASTRA includes about 5% of the total population with diagnosed HIV in the UK. Participants of ASTRA were similar to the UK HIV-diagnosed population in terms of age distribution, and the proportion who were currently receiving ART. 9 However, compared with the UK HIV-diagnosed population, ASTRA contains smaller proportions of black African people and women, but includes a higher percentage of men who have sex with men (MSM). 9 Ethical approval was granted by the North West London REC 2 ethics committee (ref 10/H0720/70) and written informed consent was granted.
The second dataset, relating to the general population, was derived from the 2011 Health Survey for England (HSE). 10 The HSE is an annual study designed to measure health and health-related behaviours in people living in a random sample of private households in England; it excludes people who are homeless or living in communal buildings such as nursing homes. Participants are interviewed at home and later visited by a nurse to collect more detailed clinical information. The 2011 survey includes interviews for 8503 people aged 18 or older. The response rate was 66%; but no information about HIV status is recorded. Ethical approval to use the survey data was obtained from the Oxford A Research Ethics Committee (reference number 10/H0604/56). Oral consent was gramted.
HRQoL was defi ned with the generic Euroqol questionnaire (EQ-5D-3L) instrument which was used in both studies. 11 Evidence suggests that this instrument exhibits good psychometric properties in terms of its use in the measurement of HRQoL in the general population 12 and in people with HIV. 13, 14 The EQ-5D-3L consists of a classifi cation system that measures current health on fi ve domains (mobility, self-care, ability to do usual activities, pain or discomfort, and anxiety/depression), each with three levels (indicating no, some, or extreme problems). The (3⁵=243) combinations of categories can be scored, or valued, with available country specifi c so-called utility algorithms (EQ-5D-3L utility ). 15 Utilities are measured on interval scales, for which perfect health (no problems on all fi ve domains) is equivalent to a value of 1 and death is equivalent to a value of 0. These scales are assumed to represent the strength of preference for specifi c healthrelated outcomes. For example, a health state with a value of 0·4 is preferred twice as much as a health state with a value of 0·2.
Statistical analysis
Responses were included if participants completed all fi ve EQ-5D-3L domain questions and were at least 18 years of age. Unadjusted diff erences in demographic variables and in EQ-5D-3L domains between the HIV and general population samples were assessed by χ² tests for proportions and Wilcoxon rank sum tests for (nonnormally distributed) continuous variables. Regression modelling was used to estimate unadjusted and adjusted diff erences in EQ-5D-3L utility scores compared between the HIV sample and the general population sample.
Provisional inspection of the EQ-5D-3L utility data showed they were non-normally distributed, with a spike at 1·0, indicating a fairly high proportion of individuals reporting perfect health. For this reason, a two-part regression model was used for the multivariable analysis. This analysis involved fi tting two regression models, the results of which are combined to produce a marginal eff ect for every independent variable. First, a logistic regression was done, in which the dependent variable indicated perfect health (yes or no). Generalised linear modelling was then done for the data relating to people with less than perfect health, with a γ distribution and log link because of the left skewed nature of the data; proportionately few individuals indicated particularly poor HRQoL. The modelling was done with the -tpmroutine for STATA v13.1. In this analysis, negative eff ect estimates indicate poorer health whereas positive values indicate better health.
The choice of which independent variables to include in models was restricted for two reasons. First, they needed to be common to both the ASTRA and HSE datasets. This ruled out for example, variables indicating homelessness, hepatitis C status, and recreational drug use (available only in ASTRA). Second, the possibility of endogeneity was a particular concern. That is, although variables such as employment status might infl uence HRQoL, there is a plausible loop in causality because HRQoL might also aff ect employment status (for example poor health could lead to loss of employment). In this sense, such an independent variable could be seen as an outcome of, or proxy measure for, HRQoL as well as a predictor of it, which is problematic in interpretation of the results. Therefore employment status, long-term sickness, and alcohol use were not judged as potential independent A series of multivariable models were used to assess the eff ect of study sample on HRQoL after adjustment for potential confounders. In model 1, only study sample (HIV sample compared with general population), age, and sex/ sexuality were included. Model 2 divides the HIV sample into two groups (CD4 count greater than 200 cells per μL and 200 cells per μL or less); additional analysis (not shown) showed that including CD4 count bandings at levels greater than 200 cells per μL did not signifi cantly add to the results. Adjustment for smoking status and other demographic variables (age, ethnic origin, sex/sexuality, having children, and maximum educational qualifi cations) were also included in model 2. Model 3 was identical to model 2 except that the HIV sample was categorised in terms of treatment status and viral load (on ART with viral load ≤50 copies per mL; on ART with viral load >50 copies per mL; stopped ART; never started ART) rather than by CD4 cell count. Model 4 combined the two methods of categorisation of the HIV sample, resulting in eight HIV categories being compared with the general population sample. Model 5 categorised the HIV sample in terms of calendar year of diagnosis. Additionally, all fi ve models were reanalysed to assess whether the eff ect of age on HRQoL was diff erent in the HIV sample compared with that in the general population sample. That is, the models were rerun including an interaction term between study sample (HIV sample compared with general population) and age (as a continuous variable).
A potential problem of the use of parametric models such as two-part regression models to account for imbalances in covariates is that they can be highly sensitive to the choice of functional form of the regression models (eg, inclusion of higher order terms in the logistic regression model). Recent methodological work has shown the advantages of matching approaches, which aim to create covariate balances between the groups being compared. Application of the parametric models on a well matched dataset is expected to decrease sensitivity to functional form mis-specifi cation. 16 Thus, a sensitivity analysis was done by rerunning model 1 after creation of a one-to-one matched HSE dataset with the genetic matching approach described by Sekhon 17 (full methodological details are available on request). The datasets were matched on age, sex, smoking status, children, ethnic origin, and educational qualifi cations, but not MSM because there were too few MSM in the HSE dataset. Model 1 was also reanalysed; fi rst, after removal of all MSM and all people who had retired from both datasets, and second, after further removal from ASTRA, of homeless people, those who had taken any recreational drugs in the past 3 months, and everyone who had ever been diagnosed with hepatitis C. Finally, despite concerns about alcohol use as a predictor of HRQoL, the original models 1-5 were rerun with adjustment for heavy drinking, defi ned as drinking at least 20 units of alcohol per week (yes or no).
Role of the funding source
The funder of the study had no role in the study design or conduct, data collection, analysis, or interpretation, preparation of the report, or the decision to submit for publication. AM had full access to the data and responsibility for the decision to submit the report for publication.
Results
3151 (96·7%) of 3258 participants of ASTRA had complete EQ-5D 3L utility data and 7424 (87·3%) of 8503 participants of the HSE. People diagnosed with HIV were signifi cantly younger than those in the general population sample by roughly 4 years (median 45·2 years, IQR 38·9-50·9 vs 49·0 years, 35·0-64·0; p<0·0001). People with HIV were also signifi cantly more likely to be MSM and heavy smokers and to have higher levels of education than people without HIV, but they were less likely to be heavy drinkers (table 1). The higher proportion of MSM in the ASTRA study than in the HSE was unsurprising, but particularly noticeable (table 1) . About 5% (n=170) of ASTRA participants had a CD4 count less than 200 cells per μL, 12% had never started ART, and overall 75% had a viral load of 50 copies per mL or less (table 1) .
The unadjusted results show that, despite being younger, people with HIV recorded lower levels of health compared with the general population on all fi ve EQ-5D-3L domains (table 2) . The anxiety/depression domain was the most markedly reduced, with 24% and 8% absolute diff erences in the proportions of people who reported at least some problems and severe problems in the two samples. The mean EQ-5D-3L utility score was 0·74 for the HIV sample and 0·82 for the general population sample. The unadjusted diff erence in overall EQ-5D-3L utility score was -0·08 (95% CI -0·09 to -0·07).
Model 1 suggests that people with HIV had signifi cantly lower EQ-5D-3L utility scores than those in the general population after adjustment for diff erences in age and sex/sexuality (-0·11 [95% CI -0·13 to -0·10]; table 3). Model 2 shows that adjustment for additional factors (ethnic origin, children, education, and smoking status) did not explain any of the diff erence in EQ-5D-3L utility between the two samples. Of people with HIV, both the group with CD4 counts of 200 cells per mm³ or less and the group with higher CD4 cells counts had signifi cantly lower EQ-5D-3L utility scores than did the general population sample (table 3) ; the diff erence between the two CD4 cell count categories was statistically signifi cant (-0·04, 95% CI -0·08 to -0·005).
The results from models 3 and 4 were similar in so much that people with HIV consistently recorded lower EQ-5D-3L utility scores than did the general population, across ART, viral load, and CD4 cell count categories (tables 3 and 4). In particular, the diff erence in EQ-5D-3L utility for people with HIV who were virally suppressed with CD4 counts greater than 200 cells per μL compared with the general population was -0·11 (95% CI -0·13 to -0·09). Model 5 clearly indicates that calendar year of HIV diagnosis was signifi cantly associated with EQ-5D-3L utility scores, people diagnosed more recently had increased HRQoL, even after accounting for age and the other covariates (table 5). In models 2-5, in addition to HIV status, older age, nonwhite ethnic origin, female sex, not having children, less education, and present and ex-smoking status were also independently associated with reduced EQ-5D-3L utility scores (tables 3-5).
When included, the interaction term between study sample (HIV sample compared with general population) and age was not statistically signifi cant in any of the models (p>0·05 in all instances). In other words, there was no evidence that the diff erence in EQ-5D-3L utility score between the two population samples became greater or smaller with changing age.
The results form model 1 remained largely unchanged when they were rerun with the matched dataset (adjusted diff erence between samples: -0·10; 95% CI -0·12 to -0·08). The results were also similar after removal of all MSM and people who had retired from both datasets and after removal of of homeless people, those who had taken any recreational drugs in the past 3 months, and people who had been ever diagnosed with hepatitis C from ASTRA (adjusted diff erence between samples: -0·08; 95% CI -0·10 to -0·06). Adjustment of models 1-5 for heavy drinking had negligible eff ects on the results (data not shown). 
Discussion
To our knowledge, this is the largest cross-sectional study to compare a standardised measure of HRQoL in people living with HIV in the era of ART directly with the general population, in a setting with universal access to health care, with the ability to simultaneously adjust for multiple potential confounders (panel). 4 Several multivariable models were constructed with diff erent categorisations of HIV status, but they consistently showed that people diagnosed with HIV had reduced HRQoL compared with the general population, across all ART, CD4, and viral load categories. In particular, the diff erence was apparent even in people who were virally suppressed on ART. Although anxiety/depression levels were the most noticeably aff ected, all fi ve EQ-5D-3L domains were reduced suggesting that HIV infection continues to have systemic health implications. This eff ect was greatest in those people diagnosed for the longest time (model 5). Despite the overall impact of HIV, we did not fi nd any evidence that the diff erence in HRQoL between those people living with HIV and the general population sample was greater with older age. These results can be used to quantify the average loss in HRQoL resulting from each newly diagnosed person with HIV. For example, with the results from model 1, and supposing that life expectancy is for 40 years after HIV diagnosis but is (conservatively) unaff ected by it, the loss is equivalent 4·4 (undiscounted) years of perfect health, or QALYs, per infection. This loss would reduce to 2 QALYs if the aff ect of infection was assumed to be -0·05, which was the utility reduction for people infected between 2010-12 in model 5.
The multivariable analyses showed that in addition to HIV status, factors such as non-white (compared with white) ethnic origin and female (compared with heterosexual male) sex were also independently associated with reduced EQ-5D-3L utility scores. Thus, these demographic groups seem to be among the most disadvantaged in terms of present levels of health.
The major strengths of this study are that it contains a large number of people with HIV in England (>3000, about 5% of all diagnosed patients in the UK), both studies were contemporaneous, had satisfactory response rates, are reasonably representative of the populations of interest, and some major potential confounding factors such smoking status were adjusted for. Additionally, recruitment in both studies took place in a way that would not be expected to select strongly for healthier participants; ASTRA recruited from hospital clinics and participants of HSE were visited in their homes. Further, the studies were done in a setting with universally free health care, which is likely to reduce the potential for confounding by access to health care. Although nonresponse rates were similar in each study, bias would be introduced if characteristics of non-responders diff ered between the studies. For example, if people with poorer physical or mental health were less likely to participate in HSE, but this was not the case for participation in ASTRA, the HSE study population would contain people with greater than average levels of health, and the diff erences in HRQoL we noted would be overestimates.
The proportion of people who participated in HSE or ASTRA who did not complete all fi ve EQ-5D-3L questions, and therefore were excluded from the analyses, was 9% greater in the HSE sample. Although so-called response fatigue could partly explain this diff erence, because HSE participants were required to answer a much longer set of questions, whether this introduces bias into the analysis or the plausible eff ect of it is unknown. For example, perhaps people in HSE who had no ill health elected not to complete the instrument, meaning the diff erences in HRQoL we report are an underestimate. Conversely, people in HSE might have been too ill to complete all the questions, which would lead to an overestimation of diff erences.
The diff erences in health that we report might not be a direct result of HIV infection, but could result in part from other unmeasured diff erences between the ASTRA and HSE populations. Moreover, we did not make multivariable adjustments for all potentially confounding factors, such as homelessness and hepatitis C status, because the information was not available in both datasets. However, adjustments for major potential The HSE study included a much lower proportion of self-reported MSM, who could for example, have diff erent levels of psychological wellbeing compared with other men. 18 Although this factor alone does not explain the diff erence in HRQoL between the two population samples because removal of all MSM from both samples had little eff ect on the results, the extent to which this issue confounds the results is unknown. Studies comparing HRQoL between HIV-positive and HIVnegative MSM would shed light on this issue.
Although HSE does not record HIV status, and is therefore likely to include people with HIV, we do not deem this to detract from the analysis because HSE participants were randomly selected and the prevalence of HIV infection in the UK is about 1·5 in 1000, meaning that HSE is predicted to contain around ten people with HIV.
Several recent studies have measured HRQoL in people living with HIV, [19] [20] [21] but few have directly compared levels with those recorded in the general population. 2, 8, 22 A large US study 6 of data from 2009 showed that the prevalence of depression was three-times higher in people with HIV than in the general population. Adjustments were made for several potentially confounding factors such as age, sex, and educational levels, but not for factors such as smoking and stage of HIV infection. However, because a third of people living with HIV in the USA are thought not to be accessing regular care, 23 the potential for confounding by access to health care is greater in the USA study.
Previous studies have consistently concluded that individuals diagnosed with HIV have high levels of depression. 4, 24, 25 Our study noted higher levels of selfreported anxiety/depression in the HIV sample than in the general population, even after adjustment for several other confounding variables such as smoking status and immunological or virological status. This high prevalence of depression among people living with HIV could be because of a range of factors including those related to living with a chronic disease, social circumstances, relationship issues, stigma, or the eff ects of specifi c drugs. The extent to which elevated anxiety/depression evident in MSM living with HIV are also apparent in HIV-negative MSM is unknown. Some evidence suggests that a high prevalence of depression exists independently of HIV status in groups such as MSM. 18 Whatever the underlying drivers of the diff erence in anxiety/depression between those with and without HIV, the fi ndings further emphasise the importance in identifi cation of those people with HIV who have psychological symptoms and in off ering appropriate care. The results suggest this is particularly true for people who were diagnosed in the earlier period of the epidemic and have been living with HIV for many years (model 5, because such people were diagnosed with the infection at a time when HIV prognosis was particularly poor. With available treatment, HIV has been transformed into a chronic disease with life expectancy approaching that of the general population. However, although we noted no evidence that the diff erence in HRQoL between the two population samples becomes greater or smaller with increasing age, HRQoL remains signifi cantly lower in people with HIV, even in those people who are virologically suppressed on ART. A substantial part of the diff erence in HRQoL is attributable to the higher levels of self-reported anxiety/ depression in people with HIV. The British HIV Association has clearly set out guidance for appropriate mental health services for people with HIV, with the aim of detecting early psychological diffi culties and providing appropriate therapeutic support for those who require it. 26 There is a well established evidence base on the effi cacy of several treatment approaches and such interventions that focus on the psychological needs of people living with HIV should be a priority.
